The company said, "Achieved highest ever cash collections at 110% of revenue for testing services, representing an approximately 10% year-over-year increase demonstrating strong operational progress on this key initiative. Grew patient test results approximately 14% year-over-year with approximately 47,700 tests. Q4 test volume included approximately 2,300 tests for AlloSure(R) Lung . Announcement of the new International Society of Heart and Lung Transplantation (ISHLT) guidelines supported the expanded use of CareDx’s HeartCare solutions, AlloMapO and now AlloSure, in routine monitoring of heart transplant patients. Commenced authorized share buyback program of up to $50 million. Program demonstrates Board of Directors’ and management’s confidence in the business, cash position and long-term growth opportunities. Maintained strong balance sheet with approximately $292 million cash, cash equivalents, and marketable securities, and no debt."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CDNA:
